New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Pacira BioSciences, Inc.
PCRX
Shape
US Flag

NASDAQ

790M

Drug Manufacturers - Specialty & Generic

Next Earning date - 07 Nov 2024

790M

Drug Manufacturers - Specialty & Generic

Next Earning date - 07 Nov 2024

17.12USD
Shape-0.01 ( -0.06%)
Market Open
favorite-chart

Relative Strenght

25
favorite-chart

Volume Buzz

-93%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

52%

Quote Panel

Shape
Updated October 29, 2024
1W -1.38 % 1M 13.89 % 3M -12.28 % 1Y -38.30 %

Key Metrics

Shape
  • Market Cap

    789.69M


  • Shares Outstanding

    46.13M


  • Share in Float

    44.59M


  • Dividende

    0


  • Earning Date

    07 Nov 2024


  • Price Target

    17.12


  • Average Volume

    1.13M


  • Beta

    0.839


  • Range

    11.16-35.95


  • Industry

    Drug Manufacturers - Specialty & Generic


  • Website

    https://www.pacira.com


  • Sector

    Healthcare


Fundamentals

Shape

5.49x

P/E Ratio

1.15x

P/S Ratio

0.90x

P/B Ratio

0.7

Debt/Equity

9.2%

Net Margin

$1.3

EPS

How PCRX compares to sector?

P/E Ratio

Relative Strength

Shape

PCRX

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$654M

Shape267%

2025-Revenue

$1.53

Shape274%

2025-EPS

$125M

Shape150%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

RBC Capital

downgrade

Previous: Underperform

2024-08-12

Now: Sector Perform

Raymond James

downgrade

Previous: Underperform

2024-08-12

Now: Market Perform

Piper Sandler

downgrade

Previous: Buy

2024-08-12

Now: Neutral

Barclays

downgrade

Previous: Not converted

2024-07-03

Now: Equal-Weight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-11%

0.64
vs 0.72

Q4.22

arrow
arrow

-18%

0.8
vs 0.97

Q1.23

arrow
arrow

-17%

0.53
vs 0.64

Q2.23

arrow
arrow

+53%

0.78
vs 0.51

Q3.23

arrow
arrow

+13%

0.72
vs 0.64

Q4.23

arrow
arrow

+11%

0.89
vs 0.8

Q1.24

arrow
arrow

+17%

0.62
vs 0.53

Q2.24

arrow
arrow

+14%

0.89
vs 0.78

Q3.24

arrow
arrow

-2%

0.7
vs 0.72

Q4.24

arrow
arrow

-9%

0.81
vs 0.89

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+31%

167.5M  vs 127.7M

Q4.22

arrow
arrow

+8%

172M  vs 159.2M

Q1.23

arrow
arrow

+1%

160.3M  vs 158M

Q2.23

arrow
arrow

+0%

169.5M  vs 169.4M

Q3.23

arrow
arrow

-2%

163.9M  vs 167.5M

Q4.23

arrow
arrow

+5%

181.2M  vs 172M

Q1.24

arrow
arrow

+4%

167.1M  vs 160.3M

Q2.24

arrow
arrow

+5%

178M  vs 169.5M

Q3.24

arrow
arrow

+3%

169.5M  vs 163.9M

Q4.24

arrow
arrow

-2%

178M  vs 181.2M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

0%

-0.00
vs 0.03

Q4.22

arrow
arrow

-1%

-0.01
vs -0.00

Q1.23

arrow
arrow

-3%

-0.03
vs -0.01

Q2.23

arrow
arrow

+3%

0.03
vs -0.03

Q3.23

arrow
arrow

+1%

0.01
vs 0.03

Q4.23

arrow
arrow

+3%

0.03
vs 0.01

Q1.24

arrow
arrow

+1%

0.01
vs 0.03

Q2.24

arrow
arrow

+2%

0.02
vs 0.01

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

268

268
vs 287

-7%

Q4.22

arrow
arrow

274

274
vs 268

2%

Q1.23

arrow
arrow

274

274
vs 274

NA

Q2.23

arrow
arrow

260

260
vs 274

-5%

Q3.23

arrow
arrow

263

263
vs 260

1%

Q4.23

arrow
arrow

267

267
vs 263

2%

Q1.24

arrow
arrow

280

280
vs 267

5%

Q2.24

arrow
arrow

288

288
vs 280

3%

Earnings Growth

Latest News